Puma Biotechnology(NASDAQ) PBYI

Market Cap$391.42M

Since IPO (2012)-43%

5 Year+12%

1 Year+150%

1 Month-7%

$7.76

+0.91%

+0.07Today

Puma Biotechnology last closing stock price
Metric	Price	Date
Last close	USD 7.69	2026-08-03

Puma Biotechnology stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-3.75%	USD 7.99	2026-07-27
1 month	-6.9%	USD 8.26	2026-07-02
3 month	+4.63%	USD 7.35	2026-05-05
Year to date	+29.24%	USD 5.95	2025-12-31
1 year	+150.49%	USD 3.07	2025-08-01
3 year	+101.31%	USD 3.82	2023-08-04
5 year	+12.26%	USD 6.85	2021-08-04
Since inception	-43.04%	USD 13.50	2012-04-20

Puma Biotechnology Financials at a Glance

Market Cap

$391.42M

Revenue (TTM)

$227.18M

Net Income (TTM)

$24.38M

EPS (TTM)

$0.48

P/E Ratio

16.11

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$7.76

Volume

3,786.782

Open

$7.71

Price

$7.76

Volume

3,786.782

Open

$7.71

Previous Close

$7.69

Daily Range

$7.71 - $7.74

52-Week Range

$3.05 - $8.75

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$7.76

Volume

3,786.782

Open

$7.71

Previous Close

$7.69

Daily Range

$7.71 - $7.74

52-Week Range

$3.05 - $8.75

Estimated Earnings Date

Aug 6, 2026

PBYI News

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

Maxx ChatskoApr 1, 2020

3 High-Risk, High-Reward Stocks That Have Massive Upside Potential

Mark PrvulovicFeb 29, 2020

Will Puma Biotechnology Break Out of Its Rut in 2020?

Maxx ChatskoFeb 28, 2020

Page 1

PBYI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Puma Biotechnology

Puma Biotechnology creates drugs to treat cancer. These medicines help patients with specific breast cancers. The company also tests new treatments for lung cancer.

What Does Puma Sell?

NERLYNX Tablets: Daily pill for adults with early-stage breast cancer who have high levels of HER2 protein; HER2 is a protein that can help cancer cells grow faster.
Combination Therapy: Medicine used with chemotherapy to treat breast cancer that has spread to other parts of the body.
Alisertib Program: Investigational drug candidates designed to stop cancer cells from dividing and growing in patients with lung or breast cancer.

Expanding the Cancer Pipeline

Licensed worldwide research and development rights for alisertib from Takeda Pharmaceutical Company Limited in September 2022.
Launched the Phase II ALISCA-Lung1 clinical trial for patients with a fast-growing type of lung cancer in 2024.
Achieved full patient enrollment for the Phase II ALISCA-Breast1 clinical trial in February 2026.
Secured marketing approvals for its lead medicine in more than 40 countries through several international sub-license agreements.

How the Business Operates

Puma Biotechnology uses a specialized sales team of 35 people to reach doctors in the United States. The company expands its reach globally by signing license deals with regional healthcare partners to distribute its treatments.

Measuring the Latest Results

Revenue rose to $75.5 million in Q4 2025, up 27.8% from $59.1 million in Q4 2024.
Gross profit reached $52.3 million in Q4 2025, a 15.8% increase over the previous year.
Operating income grew to $17.1 million in Q4 2025, up 27.9% from the 2024 period.
Net income was $13.4 million in Q4 2025, down 30.6% from $19.3 million in Q4 2024.

The Company's Evolution

Puma has grown from a research firm into a company with a selling drug and a new clinical pipeline. Its strategy relies on developing medicines for very specific types of cancer cells.

AI Generated • May 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

179

CEO

Alan H. Auerbach

Website

www.pumabiotechnology.com

Headquarters

Los Angeles, CA 90024, US

PBYI Financials

Key Financial Metrics (TTM)

Gross Margin

74.46%

Operating Margin

12.98%

Net Income Margin

10.73%

Return on Equity

20.37%

Return on Capital

23.48%

Return on Assets

12.65%

Earnings Yield

6.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$391.42M

Shares Outstanding

50.90M

Volume

3.79K

Avg. Volume

312.58K

Financials (TTM)

Gross Profit

$169.15M

Operating Income

$29.49M

EBITDA

$44.91M

Operating Cash Flow

$53.61M

Capital Expenditure

-$10.00K

Free Cash Flow

$53.60M

Cash & ST Invst.

$101.55M

Total Debt

$15.95M

Puma Biotechnology Performance Analysis

Puma Biotechnology annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 228,031,000	-9.9%
2023	2023-12-31	USD 235,637,000	3.3%
2024	2024-12-31	USD 230,468,000	-2.2%
2025	2025-12-31	USD 228,371,000	-0.9%

Puma Biotechnology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	14.0%
Q3	2025-09-30	3.9%
Q4	2025-12-31	38.5%
Q1	2026-03-31	-40.6%

Puma Biotechnology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.00	N/A
2023	2023-12-31	USD 0.45	N/A
2024	2024-12-31	USD 0.62	35.8%
2025	2025-12-31	USD 0.61	-0.4%

Puma Biotechnology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	101.3%
Q3	2025-09-30	41.7%
Q4	2025-12-31	52.9%
Q1	2026-03-31	-128.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$44.81M

-2.6%

Gross Profit

$34.39M

-3.0%

Gross Margin

76.74%

N/A

Market Cap

$391.42M

N/A

Market Cap/Employee

$2.19M

N/A

Employees

179

N/A

Net Income

-$3.75M

-226.2%

EBITDA

-$196.00K

-102.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$101.55M

+9.0%

Total Debt

$15.95M

-74.1%

Accounts Receivable

$26.33M

+4.6%

Inventory

$8.69M

-0.7%

Long Term Debt

$4.55M

-57.3%

Short Term Debt

$11.41M

-77.7%

Return on Assets

12.65%

N/A

Return on Invested Capital

22.18%

N/A

Free Cash Flow

$15.42M

+334.1%

Operating Cash Flow

$15.42M

+326.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ABEOAbeona Therapeutics Inc.

ABEOAbeona Therapeutics Inc.$6.56+2.66%

AVIRAtea Pharmaceuticals, Inc.

AVIRAtea Pharmaceuticals, Inc.$4.62+0.22%

TRDAEntrada Therapeutics, Inc.

TRDAEntrada Therapeutics, Inc.$7.61+4.75%

ELDNEledon Pharmaceuticals, Inc.

ELDNEledon Pharmaceuticals, Inc.$3.44+0.29%

SGMTSagimet Biosciences Inc.

SGMTSagimet Biosciences Inc.$7.57+5.80%

VYGRVoyager Therapeutics, Inc.

VYGRVoyager Therapeutics, Inc.$3.04+1.33%

ARCTArcturus Therapeutics Holdings Inc.

ARCTArcturus Therapeutics Holdings Inc.$6.01+0.17%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$10.05+0.07%

PLTRPalantir Technologies

PLTRPalantir Technologies$147.42+0.17%

AMIXAutonomix Medical

AMIXAutonomix Medical$6.30+0.73%

CIFRCipher Mining

CIFRCipher Mining$21.94-0.09%

SNAPSnap

SNAPSnap$5.55+0.10%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.56-0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.11+0.05%

Questions About PBYI

What is the current price of Puma Biotechnology?

Puma Biotechnology is trading at $7.74 per share.

What is the 52-week range for Puma Biotechnology?

Over the past 52 weeks, Puma Biotechnology has traded between $3.05 and $8.75.

How much debt does Puma Biotechnology have?

As of the most recent reporting period, Puma Biotechnology reported total debt of $15.95M.

How much cash does Puma Biotechnology have on hand?

Puma Biotechnology reported $38.28M in cash and cash equivalents in its most recent financial results.

What is Puma Biotechnology’s dividend yield?

Puma Biotechnology does not currently have a dividend yield.

Puma Biotechnology(NASDAQ) PBYI

Puma Biotechnology Financials at a Glance

PBYI News

Puma (PBYI) Q2 Revenue Rises 11%

Why Shares of Puma Biotechnology Rose This Week

Why Puma Biotechnology's Shares Jumped 20% on Monday

Why Puma Biotechnology Shares Dropped 17.7% This Week

Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

3 High-Risk, High-Reward Stocks That Have Massive Upside Potential

Will Puma Biotechnology Break Out of Its Rut in 2020?

PBYI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Puma Biotechnology

What Does Puma Sell?

Expanding the Cancer Pipeline

How the Business Operates

Measuring the Latest Results

The Company's Evolution

PBYI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Puma Biotechnology Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PBYI

What is the current price of Puma Biotechnology?

What is the 52-week range for Puma Biotechnology?

How much debt does Puma Biotechnology have?

How much cash does Puma Biotechnology have on hand?

What is Puma Biotechnology’s dividend yield?

Premium Investing Services